On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Institute of Clinical Cancer Research

InstitutionResearch output, impact & collaborations

Institute of Clinical Cancer Research is a institution indexed in ScholarIQ from OpenAlex.

What is known about Institute of Clinical Cancer Research?

ScholarIQrecord summary

Institute of Clinical Cancer Research is a research organisation in Frankfurt am Main, DE. OpenAlex records 859 works and 67,837 citations for it. 238 researchers list it as their most recent affiliation.

How many works does Institute of Clinical Cancer Research have?

ScholarIQindexed works

Institute of Clinical Cancer Research has 859 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Institute of Clinical Cancer Research have?

ScholarIQcitation count

Institute of Clinical Cancer Research has 67,837 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at Institute of Clinical Cancer Research?

ScholarIQresearcher count

Institute of Clinical Cancer Research has 238 researchers in the ScholarIQ index.

What is the average h-index at Institute of Clinical Cancer Research?

ScholarIQavg h-index

Institute of Clinical Cancer Research has an average h-index of 54 in OpenAlex.

What is the ROR of Institute of Clinical Cancer Research?

ScholarIQror

The ROR for Institute of Clinical Cancer Research is on the source record.

What is the OpenAlex record for Institute of Clinical Cancer Research?

ScholarIQopenalex

The OpenAlex for Institute of Clinical Cancer Research is on the source record.

Who are the most-cited researchers behind Institute of Clinical Cancer Research?

ScholarIQtop researchers by citations
1
Salah‐Eddin Al‐Batran · Gastric Cancer Management and Outcomes
371 works18,092 citations

What are the most-cited papers on Institute of Clinical Cancer Research?

ScholarIQmost cited works
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk, Hans‐Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Johannes Meiler, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst, Michael Koenigsmann, Matthias Egger, Nicole Prasnikar, Karel Caca, Jörg Trojan, Uwe M. Martens, Andreas Block, Wolfgang Fischbach, Rolf Mahlberg, Michael Clemens, Gerald Illerhaus, Katja Zirlik, Dirk Behringer, Wolff Schmiegel, Michael Pohl, Michael Heike, Ulrich Ronellenfitsch, Martin Schüler, Wolf O. Bechstein, Alfred Königsrainer, Timo Gaiser, Peter Schirmacher, Wael Hozaeel, Alexander Reichart, Thorsten Oliver Goetze, Mark Sievert, Elke Jäger, Stefan Mönig, Andrea Tannapfel
The Lancet Oncology. 2016742 Citations
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah‐Eddin Al‐Batran, Eric Van Cutsem, David H. Ilson, María Alsina, Ian Chau, Jill Lacy, Michel Ducreux, Guillermo Ariel Mendez, Alejandro Molina Alavez, Daisuke Takahari, Wasat Mansoor, Peter C. Enzinger, Vera Gorbounova, Zev A. Wainberg, Susanna Hegewisch‐Becker, David Ferry, Ji Lin, Roberto Carlesi, Mayukh Das, Manish A. Shah, Alexander Luft, Nina Karaseva, Rubén Dario Kowalyszyn, Carlos Alberto Hernández, Tibor Csőszi, Ferdinando De Vita, Per Pfeiffer, Naotoshi Sugimoto, Judit Kocsis, Andràs Csilla, G. Bodoky, Georgina Garnica Jaliffe, Светлана Проценко, Ayman Madi, Elżbieta Wójcik, Baruch Brenner, Gunnar Folprecht, Tomasz Sarosiek, Katriina Peltola, Peter Bono, Hubert Ayala, Giuseppe Aprile, Cardellino Giovanni Gerardo, Fidel David Huitzil Melendez, Alfredo Falcone, Francesco Di Costanzo, Moustapha Tehfe, Laurent Mineur, Pilar Alfonso, Radka Obermannová, Hélène Senellart, Russell Petty, Leslie Samuel, Péter Ács, Maen Hussein, M. Nechaeva, Frans Erdkamp, Elizabeth Won, Johanna C. Bendell, Javier Gállego, Sylvie Lorenzen, Bohuslav Melichar, Miguel Angel Escudero, Denis Pezet, Jean–Marc Phelip, Diego Kaen, James A. Reeves, Federico Longo Muñoz, Srinivasan Madhusudan, Carlo Barone, Luis Fein, Ángel Gómez Villanueva, Mohamed Hebbar, Jana Prausová, L. Visa Turmo, J. Vidal Barrull, Mette Yilmaz, Alex Beny, Hanneke W.M. van Laarhoven, Brian DiCarlo, Taito Esaki, Kazumasa Fujitani, Karen Geboes, Ravit Geva, Shigenori Kadowaki, Stephen Leong, Nozomu Machida, Moses S. Raj, Francisco Javier Ramírez Godinez, Ágnes Ruzsa, Hugo Ford, William Lawler, Nicolas Robert Maisey, Jiřı́ Petera, Einat Shacham‐Shmueli, Isabelle Sinapi
The Lancet Oncology. 2019285 CitationsOPEN ACCESS

How much of the research on Institute of Clinical Cancer Research is open access?

ScholarIQopen access share
50%OPEN ACCESS
Gold
0%
Green
50%
Hybrid
0%
Bronze
0%
Closed
50%

Related on ScholarIQ

470M+ articles · 14-day free trial